Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

NCT05636293 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Celiac Disease

Interventions

DRUG: Ritlecitinib
DRUG: Placebo
OTHER: Gluten

Sponsor

Massachusetts General Hospital

Collaborators

Pfizer